Compounded Semaglutide: The Shortage List and What It Means for Access
The FDA's drug shortage list has become one of the most consequential regulatory documents in modern pharmaceutical policy — particularly for semaglutide, the GLP-1 receptor agonist that has reshaped the landscape of obesity and diabetes treatment. For years, compounding pharmacies operated in a legal gray zone that allowed millions of patients to access more affordable versions of this peptide. The recent removal of semaglutide from the shortage list, and the legal battles that followed, have created significant uncertainty for researchers, clinicians, and patients alike.
How the Drug Shortage List Works
The FDA maintains a Drug Shortage Database that tracks medications whose supply cannot meet current demand. Under the Federal Food, Drug, and Cosmetic Act — specifically Section 503A and 503B — compounding pharmacies gain the legal authority to produce copies of commercially available drugs when those drugs appear on the shortage list.
This provision was originally designed as a safety valve to ensure patients could access critical medications during supply disruptions. When a branded drug is in shortage, qualified compounding pharmacies can produce chemically equivalent versions without going through the full FDA approval process.
The distinction between 503A and 503B pharmacies matters significantly. 503A pharmacies compound medications based on individual patient prescriptions, while 503B outsourcing facilities can produce larger batches without patient-specific prescriptions, though they face more stringent FDA oversight, including current good manufacturing practice (cGMP) requirements.
Semaglutide's Journey on the Shortage List
Novo Nordisk's branded semaglutide products — Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management) — experienced extraordinary demand beginning in 2022. The surge was driven by widespread recognition of GLP-1 agonists' efficacy for weight loss, fueled in part by social media attention and celebrity endorsements.
The FDA first placed semaglutide injection products on the shortage list in March 2022. According to data from the American Society of Health-System Pharmacists (ASHP), multiple dose strengths of both Ozempic and Wegovy experienced intermittent supply disruptions that persisted for over two years.
During this shortage period, compounding pharmacies began producing semaglutide at scale. Estimates suggest that by 2024, the compounded semaglutide market had grown to serve millions of patients across the United States, with some analyses valuing the market in the billions of dollars.
The Removal Decision
In October 2024, the FDA announced that semaglutide would be removed from the drug shortage list, determining that Novo Nordisk had resolved its supply issues. This decision carried enormous implications: without the shortage designation, compounding pharmacies would lose their primary legal basis for producing semaglutide.
The FDA provided a transition period, but the announcement immediately triggered pushback. The Outsourcing Facilities Association and several individual compounding pharmacies challenged the decision, arguing that the FDA's determination was premature and that genuine supply constraints persisted at the patient level.
A pivotal legal challenge came when compounding pharmacies sought emergency judicial relief. In early 2025, federal courts temporarily blocked the FDA's enforcement actions against certain compounders, creating a patchwork of legal outcomes depending on jurisdiction. The litigation centered on whether the FDA's shortage determination adequately accounted for real-world patient access barriers, including cost and insurance coverage.
The Science Behind Compounded Semaglutide
From a biochemical perspective, semaglutide is a 39-amino acid peptide that shares 94% structural homology with native human GLP-1. Its key modifications — an alpha-aminoisobutyric acid substitution at position 8 and a C-18 fatty diacid chain attached via a linker at lysine-26 — confer resistance to dipeptidyl peptidase-4 (DPP-4) degradation and enable albumin binding, resulting in a half-life of approximately 165 hours (Lau et al., 2015).
The clinical efficacy of branded semaglutide is well established. The STEP trial program demonstrated mean weight reductions of 14.9% at 68 weeks with semaglutide 2.4 mg weekly compared to placebo (Wilding et al., 2021). Cardiovascular benefits were confirmed in the SELECT trial, which showed a 20% reduction in major adverse cardiovascular events (Lincoff et al., 2023).
However, a critical question for the compounding debate is whether compounded semaglutide achieves equivalent pharmacological outcomes. Compounded versions typically use semaglutide sodium salt rather than the semaglutide base used in branded products. The FDA has raised concerns about whether the salt form is pharmaceutically equivalent and whether compounding pharmacies can consistently achieve the sterility, potency, and stability required for injectable peptide products.
Quality and Safety Considerations
The quality control debate is not theoretical. The FDA has issued multiple warning letters to compounding pharmacies producing semaglutide, citing issues ranging from potency failures to sterility concerns. In some cases, tested products contained significantly more or less active ingredient than labeled.
Key concerns identified in FDA inspections include:
Conversely, proponents of compounding argue that 503B outsourcing facilities operating under cGMP conditions can and do produce high-quality peptide products. A survey published in the Journal of the American Pharmacists Association found that compliant outsourcing facilities generally met potency and sterility specifications, though the study acknowledged significant variability across the industry.
The Access and Affordability Question
Perhaps the most compelling argument for compounded semaglutide centers on cost. Branded Wegovy carries a list price exceeding $1,300 per month, and many insurance plans either do not cover GLP-1 agonists for weight management or impose extensive prior authorization requirements. A KFF analysis estimated that if all eligible adults in the U.S. sought branded GLP-1 treatment, annual drug spending could exceed $400 billion.
Compounded semaglutide has typically been available at $150–$500 per month, depending on the pharmacy, dose, and formulation. For many patients, particularly those without insurance coverage for anti-obesity medications, this price difference represents the margin between treatment access and no treatment at all.
Research from Gasoyan et al., 2024 published in JAMA Network Open highlights the significant socioeconomic disparities in GLP-1 agonist access. Patients with lower incomes, those on Medicaid, and racial and ethnic minorities are substantially less likely to receive prescriptions for branded GLP-1 medications, even when clinically appropriate.
Regulatory Future and Emerging Alternatives
The legal and regulatory landscape continues to evolve rapidly. Several developments are worth tracking:
The FDA has also signaled interest in creating a more structured framework for peptide compounding, potentially establishing clearer quality standards that could allow continued access while addressing legitimate safety concerns (FDA Draft Guidance, 2024).